Northway Biotech
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
Innodata Awarded Prime Contract Position on U.S. Missile Defense Agency's IDIQ SHIELD Program20.1.2026 14:30:00 CET | Press release
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. The SHIELD program is designed to drive rapid innovation and deliver next-generation capabilities that strengthen the nation's multi-layered homeland defense architecture. As part of the broader Golden Dome strategy, this selection positions Innodata to compete for future task orders across research, development, engineering, prototyping, and operations of critical Missile Defense Agency systems that support U.S. national security objectives. The award was made as part of a list of companies eligible to compete under the program publicly announced by the U.S. Government on 15-Jan-26. "We are proud to support our nation's mission to defend the homeland," said Vinay Malkani, SVP Federal of Innodata. "This co
Karbon-X Secures up to $25 Million in Strategic Financing to Accelerate Growth and Expand Global Climate Solutions Platform20.1.2026 14:30:00 CET | Press release
CALGARY, AB / ACCESS Newswire / January 20, 2026 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate-solutions company operating across compliance and voluntary carbon markets, today announced that it has secured access to up to $25 million in discretionary financing, providing the Company with enhanced flexibility to scale its platform, deepen market participation, and capitalize on strategic growth opportunities as global carbon markets continue to mature. The financing supports the Company's ability to execute its growth strategy with discipline, while remaining responsive to evolving regulatory frameworks and market demand. "This financing enhances our ability to execute with focus and flexibility," said Chad Clovis, Chief Executive Officer of Karbon-X. "Access to capital allows us to scale areas of the business that are already performing, selectively invest in growth, and pursue opportunities aligned with our long-term value creation strategy." The financing is intende
Polaris Renewable Energy Declares Quarterly Dividend20.1.2026 13:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / January 20, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on February 27th to shareholders of record at the close of business on February 17th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom